Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has extended its Imatinib Mesylate Savings Card Program beyond July 31, 2016. Sun Pharma launched this program as part of the Imatinib Mesylate launch in February 2016. The program is aimed at delivering greater access to the drug by patients who have commercial insurance, but whose out-of-pocket cost may exceed an affordable amount.

As part of the Imatinib Mesylate savings card program extension, Sun Pharma will continue to offer up to $700 reduction on each eligible patient’s initial out-of-pocket cost from their commercial insurer thereby reducing the patient’s out-of-pocket co-payment to as low as $10. This benefit will cover a patient’s monthly fills for a 30-day supply of Sun Pharma’s Imatinib Mesylate prescribed for Ph+CML, a form of chronic myeloid leukemia through the extension period.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.